SCHEMBL1158433

SCHEMBL1158433

CC(C)CNc1nc(Nc2ccccn2)cc2cc[nH]c(=O)c12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ZAP70 P43403 6/20 0.40
JAK2 O60674 6/20 0.40
LYN P07948 4/20 0.40
SYK P43405 3/20 0.40
GRM5 P41594 2/20 0.38
APAF1 O14727 1/20 0.37
TDP2 O95551 1/20 0.37
CDC25B P30305 1/20 0.37
CASP6 P55212 1/20 0.37
RCE1 Q9Y256 1/20 0.37
TYK2 P29597 2/20 0.37
FER P16591 1/20 0.36
LRRK2 Q5S007 1/20 0.36
JAK1 P23458 1/20 0.35
KCNH2 Q12809 2/20 0.34
MAPK14 Q16539 1/20 0.33
SRC P12931 1/20 0.33
BTK Q06187 1/20 0.33
FLT3 P36888 1/20 0.33
EGFR P00533 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1158677 0.86 SYK (0.40) ZAP70JAK2LYNSYKTYK2
SCHEMBL1158539 0.85 ZAP70 (0.37) ZAP70JAK2LYNSYKGRM5
SCHEMBL1158516 0.84 MEN1 (0.38) ZAP70JAK2LYNSYKGRM5
SCHEMBL1158779 0.84 MEN1 (0.38) ZAP70JAK2LYNSYKGRM5
SCHEMBL1158115 0.84 JAK2 (0.43) ZAP70JAK2LYNSYKGRM5
SCHEMBL1158368 0.83 GRM5 (0.39) ZAP70JAK2LYNSYKGRM5
SCHEMBL1158263 0.83 GRM5 (0.39) ZAP70JAK2LYNSYKGRM5
SCHEMBL1158763 0.83 GRM5 (0.39) ZAP70JAK2LYNSYKGRM5
SCHEMBL1158836 0.82 JAK2 (0.40) ZAP70JAK2LYNSYKAPAF1
SCHEMBL1158330 0.82 KDM4E (0.43) ZAP70JAK2GRM5APAF1TDP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2459556-A1 2, 7 -NAPHTHYRIDIN- 1 -ONE DERIVATIVES AS SYK KINASE INHIBITORS IRM LLC (BM) 2012-06-06 EP claimed
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-03-03 US claimed
WO-2011014515-A1 2, 7 -NAPHTHYRIDIN- 1 -ONE DERIVATIVES AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-02-03 WO claimed
EP-2459556-A1 2, 7 -NAPHTHYRIDIN- 1 -ONE DERIVATIVES AS SYK KINASE INHIBITORS IRM LLC (BM) 2012-06-06 EP disclosed
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-03-03 US disclosed
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-03-03 US disclosed
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-03-03 US disclosed
WO-2011014515-A1 2, 7 -NAPHTHYRIDIN- 1 -ONE DERIVATIVES AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-02-03 WO disclosed
WO-2011014515-A1 2, 7 -NAPHTHYRIDIN- 1 -ONE DERIVATIVES AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS SYK, BTK, LYN ZAP70 5/4885JAK2 19/4885LYN 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.